Two Big Pharma Firms Quit UK Pricing Scheme In Protest Over High Levies
Executive Summary
Lilly says the current voluntary drug pricing and access scheme has harmed innovation and left the UK a “global outlier” among major countries, while AbbVie asserts that this year’s repayment rate of 26.5% will impair its ability to operate sustainably in the country. The industry body, the ABPI, says it will come up with proposals for a “completely new settlement” in the coming months.
You may also be interested in...
Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe
A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”
ABPI Chooses Pfizer’s Susan Rienow As New President
Susan Rienow, UK country president of Pfizer, is to formally replace Pinder Sahota, UK manager of Novo Nordisk, as president of the UK pharmaceutical industry trade group, the ABPI.
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.